Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 09-2020 | 06-2020 | 03-2020 | 12-2019 | |
| Sales | 91,542 | 81,470 | 61,709 | 36,309 | 35,593 |
| Cost of Goods | 5,481 | 2,348 | 1,803 | -3,503 | 5,107 |
| Gross Profit | 86,061 | 79,122 | 59,906 | 39,812 | 30,486 |
| Operating Expenses | 182,623 | 129,785 | 123,764 | 159,974 | 125,045 |
| Operating Income | -96,081 | -50,315 | -63,055 | -120,665 | -94,452 |
| Interest Expense | 8,198 | 8,582 | 8,429 | 8,082 | 0 |
| Other Income | 80,338 | -9,635 | 97,214 | 10,131 | 3,208 |
| Pre-tax Income | -23,941 | -68,532 | 25,730 | -118,616 | -91,244 |
| Income Tax | 70 | 313 | 415 | 409 | 2,561 |
| Net Income Continuous | -24,011 | -68,845 | 25,315 | -119,025 | -93,805 |
| Net Income | $-24,011 | $-68,845 | $25,315 | $-119,025 | $-93,805 |
| EPS Basic Total Ops | -0.31 | -1.13 | 0.42 | -2.05 | -1.62 |
| EPS Basic Continuous Ops | -0.30 | -1.13 | 0.42 | -2.05 | -1.62 |
| EPS Diluted Total Ops | -0.30 | -1.13 | 0.41 | -2.05 | -1.62 |
| EPS Diluted Continuous Ops | -0.29 | -1.13 | 0.41 | -2.05 | -1.62 |
| EBITDA(a) | $-92,317 | $-46,857 | $-59,721 | $-118,112 | $-93,566 |